This finding is in apparent contrast to Villarreal et al, where anti-CCR8 mAb therapy was reported to inhibit CCR8 signaling, resulting in slower tumor growth and improved survival in a mouse model of colon cancer.56 Since treatment with the mAb also resulted in a decreased frequency of CCR8+ ti-Tregs, it is likely that this anti-CCR8 mAb also resulted in Fc-mediated cell depletion.56 This evidence concerns the gene CCR8 and colonic neoplasm.